Industry Overview:
The global biosimilars market is estimated to reach USD 32.99 billion in 2025, reflecting a growth rate of 17.5%. Growth is driven by the rising demand for affordable biologic therapies across hospitals, specialty clinics and outpatient care facilities which particularly in oncology, autoimmune and diabetes treatments. The expanding patient access with increasing prevalence of chronic diseases and the loss of exclusivity for major biologics are fueling biosimilar adoption worldwide. Investments in advanced biomanufacturing technologies including AI-driven process optimization in single-use bioreactors and automated cold-chain solutions which are improving production efficiency and product quality. Supportive regulatory frameworks such as government incentives and hospital procurement programs are accelerating market penetration helps to reducing treatment costs and enabling broader access which ultimately boosting global adoption across both developed and emerging healthcare markets.
Industry Insights: Scale, Segments, and Shifts
Market Size & Growth: The global biosimilars market is projected to reach USD 162.69 billion by 2035, registering a CAGR of 17.3% between 2025 and 2035.
Segment Analysis: Biosimilar monoclonal antibodies (mAbs) account for the largest share at over 42%, owing to high usage in oncology and autoimmune therapy. Oncology indications represent the fastest-growing segment due to increasing cancer prevalence and strong payer adoption of cost-saving alternatives.
Regional Highlights: Europe leads the global market with nearly 38% share backed by strong regulatory frameworks, rapid approvals, and high physician confidence. Asia Pacific is the fastest-growing region, driven by expanding healthcare access, large patient pools, and rapid manufacturing capacity expansion.
Competitive Landscape: The market is moderately consolidated with key players such as Amgen Inc., Sandoz, and Pfizer Inc. The companies are focusing on portfolio expansion with advanced biomanufacturing in AI and single-use systems, strategic partnerships and accelerated commercialization to strengthen global presence.
Factors Shaping the Next Decade
Market Gaps / Restraints: The lack of standardized regulatory alignment across emerging markets, higher development and manufacturing costs for complex biologics and strong reliance on advanced bioprocessing supply chains limit biosimilar penetration in cost-sensitive regions.
Key Trends and Innovations: The industry is experiencing rapid adoption of AI-enabled process optimization, expansion of single use bioreactors and increased automation in quality analytics. The integration of continuous bioprocessing and advanced characterization tools is improving production efficiency and reducing development timelines.
Potential Opportunities: Growing demand for affordable biologic therapies, expanding use of biosimilars in chronic disease management and rising acceptance of interchangeable products across major healthcare systems are expected to unlock substantial growth potential in the coming years.
Recent Industry Updates:
• November 2025: Dr. Reddy’s Laboratories has received European Commission marketing authorization for AVT03 is a biosimilar to Prolia / Xgeva which enabling its launch across Europe and expanding access to bone-health biosimilars.
• July 2025: Biocon Biologics is got U.S. FDA approval for Kirsty insulin-aspart biosimilar the first interchangeable rapid-acting insulin biosimilar in the U.S. which marking a major milestone in diabetes care accessibility.
Industry Outlook Scope:
By Drug Class
• Monoclonal Antibodies (mAbs)
• Growth Factors & Hematopoietic Agents
• Insulin & Analogues
• Osteoporosis / Bone Metabolism Agents
• Others
By Indication
• Autoimmune Disorders
• Oncology
• Diabetes Mellitus
• Ophthalmic Disorders
• Hematologic / Rare Blood Disorders
• Others
By Route of Administration
• Intravenous (IV)
• Subcutaneous (SC)
• Others
By End User
• Hospitals
• Specialty Pharmacies
• Online & Retail Channels
Geographical Insights: Emerging Corridors of Growth
• Regional Overview: While In North America, growth is driven by robust healthcare infrastructure, rising chronic disease prevalence, and government incentives promoting the use of biosimilars. The Middle East & Africa is witnessing increasing demand due to expanding healthcare facilities, public-private partnerships and government programs improving access to affordable biologics. In South America, industrial modernization with local manufacturing and regulatory reforms are boosting biosimilar adoption, while healthcare infrastructure expansion supports wider patient access.
• Countries to Watch: The United States leads in biosimilar adoption supported by FDA approval pathways, payer incentives and increasing physician acceptance of interchangeable products. Canada is emerging with growing utilization programs in public healthcare systems. Brazil is a key South American hub which is benefitting from favourable regulations and investment in local biopharmaceutical production.
Regulatory Environment and Policy Support
• Government Regulations & Supportive Policies: Global biosimilars manufacturers follow the FDA Biosimilars Action Plan (BAP) in the United States and the EMA Biosimilar Framework in Europe which helps to ensuring standardized approval pathways, safety and efficacy compliance. These frameworks streamline comparability and interchangeability requirements with reduce development barriers and accelerate biosimilar approvals. The WHO Biosimilar Guidelines provide internationally harmonized quality and safety standards which supporting adoption in low- and middle-income countries.
• Key Government Initiatives: Initiatives like Canada’s Biosimilar Incentive Program, Brazil’s National Biologics Policy, and South Africa’s Biopharmaceutical Access Scheme promote biosimilar adoption through local manufacturing support which reimbursement policies and public procurement incentives. These programs help increase market uptake, broaden patient access and support cost-effective biologic therapies in their respective regions.
Competitive Landscape and Strategic Outlook
The Biosimilars industry is moderately concentrated, with leading players capitalizing on portfolio diversification with strategic acquisitions and technology partnerships to expand presence worldwide. The major players are focusing increase investment in advanced analytical platforms with scalable manufacturing capacity and robust supply chain networks which helps to ensure consistent product quality and timely delivery. The emerging manufacturers in Latin America and the Middle East such regions are focusing on cost-effective local production and regional distribution strategies to capture underserved markets. Innovative approaches such as collaborative R&D programs and licensing agreements are strengthening competitive positioning without relying on previously mentioned AI or patient-centric initiatives.
Industry Competition:
• Amgen Inc.
• F Hoffman-La Roche Ltd.
• Sandoz International GmbH
• Dr. Reddy’s Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Samsung Biopis
• Biocon
• Viatris Inc.
• Celltrion Healthcare Co., Ltd.
• AbbVie Inc.
Analyst Perspective
The biosimilars industry is shifting towards strategic expansion which driven by increasing global demand for affordable biologics and supportive regulatory frameworks. In the coming next three to five years these investments in advanced biomanufacturing technologies with help of AI-driven quality control and patient centric delivery models are expected to accelerate growth. The major Companies that focus on regional market penetration, streamlined regulatory compliance and value-based contracting will gain a sustainable competitive edge, strengthen global market share and enhance access to critical therapies across diverse healthcare systems.
What to Expect from Outlook:
1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global Biosimilars Market
2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global Biosimilars Market sector.
3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.
4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Biosimilars Market with a forecast for the decade by both market share (%) & revenue (USD Million).
1. Introduction
1.1. Executive Summary
1.2. Regional Snapshot
1.3. Market Scope
1.4. Market Definition
2. Across
The Globe
2.1. Factors Affecting End Use Industries
2.2. Market Dynamics
2.2.1. Upcoming Opportunities
2.2.2. Ongoing Market Trends
2.2.3. Growth Driving Factors
2.2.4. Restraining Factors
2.3. Value Chain Analysis
2.3.1. List of Manufacturers
2.3.2. List of Distributors/Suppliers
2.3.3. List of End Users
2.4. PORTER’s & PESTLE Analysis
2.5. Key Developments
2.6. Key Regulations & Certifications
3. Global
Biosimilars Market Overview, By Drug Class
3.1. Market Size (US$ Mn) Analysis, 2020 –
2035
3.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
3.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
3.3.1. Monoclonal Antibodies (mAbs)
3.3.2. Growth Factors & Hematopoietic Agents
3.3.3. Insulin & Analogues
3.3.4. Osteoporosis / Bone Metabolism Agents
3.3.5. Others
4. Global
Biosimilars Market Overview, By Indication
4.1. Market Size (US$ Mn) Analysis, 2020 –
2035
4.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
4.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
4.3.1.
Autoimmune Disorders
4.3.2. Oncology
4.3.3. Diabetes Mellitus
4.3.4. Ophthalmic Disorders
4.3.5. Hematologic / Rare Blood Disorders
4.3.6. Others
5. Global
Biosimilars Market Overview, By Route of Administration
5.1. Market Size (US$ Mn) Analysis, 2020 –
2035
5.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
5.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
5.3.1. Intravenous (IV)
5.3.2. Subcutaneous (SC)
5.3.3. Others
6. Global
Biosimilars Market Overview, By End User
6.1. Market Size (US$ Mn) Analysis, 2020 –
2035
6.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
6.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
6.3.1.
Hospitals
6.3.2. Specialty Pharmacies
6.3.3. Online & Retail Channels
7. Global
Biosimilars Market Overview, By Region
7.1. Market Size (US$ Mn) Analysis, 2020 –
2035
7.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
7.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Middle East & Africa
7.3.5. South America
8. North
America Biosimilars Market Overview
8.1. Market Size (US$ Mn) Analysis, 2020 –
2035
8.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
8.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
8.3.1. By Country
8.3.1.1. U.S.
8.3.1.2. Canada
8.3.1.3. Mexico
8.3.2. By Drug Class
8.3.3. By Indication
8.3.4. By Route of Administration
8.3.5. By End User
9. Europe
Biosimilars Market Overview
9.1. Market Size (US$ Mn) Analysis, 2020 –
2035
9.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
9.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
9.3.1. By Country
9.3.1.1. UK
9.3.1.2. Italy
9.3.1.3. Spain
9.3.1.4. Germany
9.3.1.5. France
9.3.1.6. BENELUX
9.3.1.7. Nordics
9.3.1.8. Rest of Europe
9.3.2. By Drug Class
9.3.3. By Indication
9.3.4. By Route of Administration
9.3.5. By End User
10. Asia Pacific Biosimilars Market Overview
10.1. Market Size (US$ Mn) Analysis, 2020 – 2035
10.2. Market Share (%) Analysis (2024 vs 2035),
Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness Analysis
(2025 - 2035)
10.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
10.3.1. By Country
10.3.1.1. China
10.3.1.2. Japan
10.3.1.3. India
10.3.1.4. South Korea
10.3.1.5. ASEAN
10.3.1.6. Australia & New Zealand
10.3.1.7. Rest of Asia Pacific
10.3.2. By Drug Class
10.3.3. By Indication
10.3.4. By Route of Administration
10.3.5. By End User
11. Middle East & Africa Biosimilars Market Overview
11.1. Market Size (US$ Mn) Analysis, 2020 – 2035
11.2. Market Share (%) Analysis (2024 vs 2035),
Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness Analysis
(2025 - 2035)
11.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
11.3.1. By Country
11.3.1.1. GCC
11.3.1.2. South Africa
11.3.1.3. Rest of Middle East & Africa
11.3.2. By Drug Class
11.3.3. By Indication
11.3.4. By Route of Administration
11.3.5. By End User
12. South America Biosimilars Market Overview
12.1. Market Size (US$ Mn) Analysis, 2020 – 2035
12.2. Market Share (%) Analysis (2024 vs 2035),
Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness Analysis
(2025 - 2035)
12.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Chile
12.3.1.3. Rest of South America
12.3.2. By Drug Class
12.3.3. By Indication
12.3.4. By Route of Administration
12.3.5. By End User
13. Country-Wise Market Analysis
13.1. Growth Comparison by Key Countries
14. Competitive Landscape
14.1. Market Share (%) Analysis, By Top Players
14.2. Market Structure Analysis, By Tier I &
II Companies
15. Company Profiles
15.1. Amgen Inc.
15.1.1. Company Overview
15.1.2. Business Segments
15.1.3. Financial Insights
15.1.4. Key Business Aspects (Noise Analysis)
15.2. F Hoffman-La Roche Ltd.
15.3. Sandoz International GmbH
15.4. Dr. Reddy’s Laboratories Ltd.
15.5. Teva Pharmaceutical Industries Ltd.
15.6. Pfizer Inc.
15.7. Samsung Biopis
15.8. Biocon
15.9. Viatris Inc.
15.10. Celltrion Healthcare Co., Ltd.
15.11. AbbVie Inc.
16. Analysis & Recommendations
16.1. Targeting Segment
16.2. Targeting Region
16.3. Market Approach
17. Research Methodology
18. Disclaimer
